ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2658

Correlation Between Mefv Genotype and Interleukin (IL)1β secretion and Role of the nlr Family Pyrin Domain Containing 3 (Nlrp3) Inflammasome in Patients with Familial Mediterranean Fever (FMF)

Alessia Omenetti1, Sonia Carta2, Delfino Laura2, Alberto Martini3, Anna Rubartelli4 and Marco Gattorno1, 1Pediatrics II Unit G Gaslini Institute, Genoa, Italy, 2Cell Biology, lST-San Martino, Genoa, Italy, 3Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 4lST-San Martino, Genoa, Italy, Genoa, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Familial Mediterranean fever and interleukins (IL)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Familial Mediterranean Fever (FMF) is an autoinflammatory disease due to mutations of MEFV gene which encodes for Pyrin. FMF does not behave as a pure recessive disorder but clinical manifestations may parallel the actual amount of mutant pyrin. In agreement with this concept, correlation between genotype and FMF symptoms has been described. Growing evidence suggests that aberrant interleukin (IL) 1β signaling occurs in FMF. However, whether genetic variants of the MEFV gene result in differences in IL1β levels has never been explored. Moreover, the role of NLR family pyrin domain containing 3 (NLRP3) inflammasome in this contest is still largely unclear. Thus, we evaluated if IL1β pathway activation (1) is enhanced in FMF; (2) correlates with the type of MEFV mutation; and (3) is mediated by NLRP3. 

Methods: Twenty FMF patients (FMFp) were evaluated and compared with 14 MEFV healthy carriers (HC) and 30 healthy donors (HD). Among patients, 12 were genetically confirmed (i.e. carrying 2 mutations) while 8 had clinical manifestations even if carrying 1 single mutation in heterozygosity. Ten out of 20 FMFp were under colchicine treatment and all of them were in controlled disease activity. Monocytes were freshly isolated and studied at baseline and after LPS in vitro activation. Monocyte nucleofection with NLRP3 siRNA or appropriate Mock controls was performed in 23 subjects (i.e. 7 FMFp, 9 HC, 3 HD) using Nucleofector™ Technology (Amaxa). IL1β and IL1 receptor antagonist (ILRa) pattern of secretion (3-6-18h) was analyzed by ELISA assay. Differences in oxydative state were evaluated by assessing levels of reactive oxygen species (ROS) and the cysteine release, as markers of pro- and antioxidant responses, respectively.

Results: Monocytes purified from FMFp displayed enhanced IL1β release. Interestingly, lL1β secretion correlated with number and penetrance of MEFV mutations, with higher levels in the presence of 2 high penetrance mutations in FMFp, and 1 high penetrance mutation in HC, respectively. Silencing of NLRP3 activity in monocytes freshly isolated from patients and controls consistently inhibited lL1β secretion. Contrary to what previously described in diseases caused by mutations that primarily affect the NLRP3 (i.e. Cryopyrinopaties) L1β release in pyrin mutated monocytes was featured by a more physiological kinetics. Consistent with this finding, FMFp monocytes basally produced more ROS but had a conserved, although impaired, cysteine release. Finally, IL1Ra levels were comparable to HD.

Conclusion: MEFV mutated monocytes display enhanced IL1β secretion, which correlates with the number of high-penetrance mutations. In contrast to what found in the animal model, IL1β secretion in FMFp monocytes is NLRP3-dependent. Interestingly, contrary to what previously reported in NLRP3 mutated cells, monocytes carrying MEFV mutation (1) have conserved antioxidant machinery capable of restraining the oxidative stress, (2) do not show stress-related defect in protein synthesis, (including IL1Ra production) and  (3) display a more physiological pattern of secretion of lL1β.


Disclosure:

A. Omenetti,
None;

S. Carta,
None;

D. Laura,
None;

A. Martini,
None;

A. Rubartelli,
None;

M. Gattorno,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-between-mefv-genotype-and-interleukin-il1%ce%b2-secretion-and-role-of-the-nlr-family-pyrin-domain-containing-3-nlrp3-inflammasome-in-patients-with-familial-mediterranean-fever-fmf/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology